About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

WITHDRAWNNCT03258801

Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis

The diagnosis of idiopathic pulmonary fibrosis (IPF) is currently one of the most common diagnoses for patients under evaluation for lung transplantation. In recent years, an absolute increase in prev...

Lead sponsor: Dr. Christopher Lambers•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Dr. Christopher Lambers

Collaborators

Medical University of Vienna

Age

40 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•For Pirfenidone Group
•mild to moderate idiopathic pulmonary fibrosis (IPF).
•Current or intended treatment with Pirfenidone
•Diagnosis of Interstitial Lung disease
•Evaluation for Lung Transplantation
•Age 40-70
•For Control Group
•mild to moderate idiopathic pulmonary fibrosis (IPF).
•Diagnosis of Interstitial Lung disease
•Evaluation for Lung Transplantation
•Age 40-70

Exclusion Criteria

•For Pirfenidone Group
•Other lung diseases (such as cystic fibrosis, COPD)
•Infection with Hepatitis C,
•Liver cirrhosis CHILD C
•Coronary heart disease (3VD)
•For Control Group
•Other lung diseases (such as cystic fibrosis, COPD)
•Infection with Hepatitis C,
•Liver cirrhosis CHILD C
•Coronary heart disease (3VD)

Related studies

RECRUITINGEARLY Phase 1

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

NCT04469842 · Lung Transplant; Complications

Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis

NCT05842681 · Idiopathic Pulmonary Fibrosis

RECRUITINGPhase 2

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

NCT06951217 · Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)

RECRUITINGPhase 2

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

NCT07194382 · Idiopathic Pulmonary Fibrosis (IPF)

RECRUITINGPhase 3

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622 · Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 27, 2020Terms

Trial snapshot

StatusWITHDRAWN

Phase—

Enrollment—

Start dateOct 2018

Last updatedJan 27, 2020

Condition

Idiopathic Pulmonary Fibrosis Lung Transplant; Complications

Locations shown

Medical University of Vienna, Department of Surgery

Vienna

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 27, 2020Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions